Size | Price | Stock | Qty |
---|---|---|---|
100mg |
|
||
500mg |
|
||
1g |
|
||
2g |
|
||
5g |
|
||
Other Sizes |
|
ln Vitro |
It was discovered that trigonelline considerably improved the morphology of H9c2 cells. Trigonelline treatment decreases H2O2-induced cell death and improves antioxidant activity in cells. Furthermore, research has demonstrated that trigonelline controls the expression of the antioxidant genes Bcl-2 and Bcl-XL as well as the oxidant genes caspase-3 and caspase-9 in H9c2 cells during the H2O2-induced oxidation process. Trigonelline chloride appears to also greatly diminish H2O2-induced H9c2 cell connections and anodes, as evidenced by flow cytometry studies [1].
|
---|---|
ln Vivo |
In streptozotocin-induced diabetes condition, trimetholine chloride decreases bone mineralization and tends to deteriorate bone mechanical characteristics. Trigonelline significantly increased bone mineral density (BMD) and tended to increase cancellus in nicotinamide/streptozotocin treated material. Trigonelline has varying effects on the induction produced by streptozotocin. has positive effects on the induction of psychiatric non-hypertension (nicotinamide/streptozotocin treatment) and strengthens the osteoporotic alterations of streptozotocin treatment [2].
|
References |
[1]. Ilavenil S, et al. Trigonelline protects the cardiocyte from hydrogen peroxide induced apoptosis in H9c2 cells. Asian Pac J Trop Med. 2015 Apr;8(4):263-8.
[2]. Joanna Folwarczna, et al. Effects of Trigonelline, an Alkaloid Present in Coffee, on Diabetes-Induced Disorders in the Rat Skeletal System. Nutrients. 2016 Mar; 8(3): 133. [3]. A Arlt, et al. Inhibition of the Nrf2 transcription factor by the alkaloid trigonelline renders pancreatic cancer cells more susceptible to apoptosis through decreased proteasomal gene expression and proteasome activity. Oncogene. 2013 Oct;32(40):4825-35. [4]. Ozçelik B, et al. Cytotoxicity, antiviral and antimicrobial activities of alkaloids, flavonoids, and phenolic acids. Pharm Biol. 2011 Apr;49(4):396-402. [5]. Su Y, et al. Ferroptosis, a novel pharmacological mechanism of anti-cancer drugs. Cancer Lett. 2020 Jul 28;483:127-13 |
Molecular Formula |
C7H8CLNO2
|
---|---|
Molecular Weight |
173.5969
|
CAS # |
6138-41-6
|
Related CAS # |
Trigonelline;535-83-1;Trigonelline-d3 chloride
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
SMILES |
[Cl-].O([H])C(C1C([H])=C([H])C([H])=[N+](C([H])([H])[H])C=1[H])=O
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ~125 mg/mL (~720.05 mM)
H2O : ~100 mg/mL (~576.04 mM) |
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (11.98 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (11.98 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (11.98 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 100 mg/mL (576.04 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 5.7604 mL | 28.8018 mL | 57.6037 mL | |
5 mM | 1.1521 mL | 5.7604 mL | 11.5207 mL | |
10 mM | 0.5760 mL | 2.8802 mL | 5.7604 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.